Table 4.
Association between methylation status of P16 and TP53 and EC prognosis.
| Variable | Cases (%) | Median survival (Months) (95% CI) |
Crude HR (95% CI) |
p-value | Adjust HR (95% CI) | p-value |
|---|---|---|---|---|---|---|
| P16 Methylation status | ||||||
| Unmethylated P16 | 22 (20.9%) | 20.2 (4.95–15.34) | 1.00 | 0.013 | 1.00 | 0.027 |
| Methylated P16 | 83 (79.1%) | 8.5 (6.83–10.17) | 2.28 (1.10–4.71) | 2.82 (1.13–5.06) | ||
| TP53 Methylation status | ||||||
| Unmethylated TP53 | 28 (26.7%) | 14.8 (4.85–24.75) | 1.00 | 0.002 | 1.00 | 0.007 |
| Methylated TP53 | 77 (73.3%) | 8.4 (6.52–10.28) | 2.37 (1.28–4.37) | 2.95 (1.34–5.47) | ||
Oesophageal cancer; (95% CI): 95% confidence interval, HR hazard ratio, P16: (cyclin-dependent kinase inhibitor 2A), TP53: (tumour protein p53), adjust for age, gender, BMI, histology type, grading, TNM state, metastasis, complication and comorbidity by using Cox proportional hazards regression models. p-value from partial likelihood ratio test.